Advertisement
Advertisement
EDIT
Editas Medicine, Inc. Common Stock
2.88
USDSponsored
+0.08
+3.04%
Jun 25, 10:52 UTC -4
Open
EDIT Earnings Reports
Positive Surprise Ratio
EDIT beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.86M
/-$0.27
Implied change from Q1 26 (Revenue/ EPS)
+0.89%
/+3.85%
Implied change from Q2 25 (Revenue/ EPS)
-20.18%
/-57.14%
Editas Medicine, Inc. Common Stock earnings per share and revenue
On May 05, 2026, EDIT reported earnings of -0.26 USD per share (EPS) for Q1 26, beating the estimate of -0.26 USD, resulting in a 3.35% surprise. Revenue reached 2.83 million, compared to an expected 4.49 million, with a -37.00% difference. The market reacted with a +1.33% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 2.86 million USD, implying an increase of 3.85% EPS, and increase of 0.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Grace Therapeutics, Inc. Common Stock
Report Date
Jun 18, 2026 For Q4 26
Estimate
-$0.23
Actual
-$0.06
Surprise
+74.42%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were Editas Medicine, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Editas Medicine, Inc. Common Stock reported EPS of -$0.26, beating estimates by 3.35%, and revenue of $2.83M, -37% below expectations.
How did the market react to Editas Medicine, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 1.33%, changed from $3.00 before the earnings release to $3.04 the day after.
When is Editas Medicine, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Editas Medicine, Inc. Common Stock's next earnings report?
Based on 9
analysts, Editas Medicine, Inc. Common Stock is expected to report EPS of -$0.27 and revenue of $2.86M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement